S&P 50 · Free
AbbVie
ABBV#PharmaceuticalsHigh stock comp
AbbVie trades at 16.77x forward earnings — 58% above peers (vs 7 peers in #Pharmaceuticals). Price $250.33.
- Forward P/E
- 16.77
- Industry median 10.64
- Current P/E
- 23.03
- Industry median 11.09
- Forward PEG
- 1.03†
- Next fiscal year
- Opportunity Score
- 10
- Below average
Forward P/Edivides today's price by the earnings analysts expect AbbVie to make over the next fiscal year — see what forward P/E measures for the full definition. Opportunity Score is a separate, slower 0–100 read on how attractive today looks as a historical entry point — see how it's built.
Consensus earnings run well above GAAP earnings, mostly through stock-based compensation. Ordinary for high-growth software, but it dilutes shareholders and makes any single earnings multiple a weaker signal.